

Remarks

The sequence listing enclosed herewith includes SEQ ID NOS:1-7. The sequence listing submitted herewith differs from the sequence listing submitted with the Amendment and Response filed on November 26, 2004, in changing the description of SEQ ID NO:1 and SEQ ID NO:2 from “synthetic” to “artificial” and adding a comment to the description of SEQ ID NO:1 and SEQ ID NO:2. Accordingly, this amended sequence listing introduces no new matter.

Telephonic Conference

Applicant thanks the Examiner for the courtesy of a telephonic conference with the Applicant’s attorney on February 28, 2005, during which the sequence listing was discussed. It was clarified to the Examiner’s satisfaction that none of the sequences in the sequence listing are identical to each other. Specifically, it was clarified that SEQ ID NO:5 is the EpoR polypeptide sequence reported by Jones et al., and SEQ ID NO:7 is the EpoR polypeptide sequence reported by Winkelman et al. The two polypeptides differ at four amino acid residues, as described in the amended specification paragraph beginning at page 2, lines 6 of the specification, found at page 2 of the Applicant’s Amendment and Response filed on November 26, 2004.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance, and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (651-207-8270) to facilitate prosecution of this application.

Respectfully submitted,

JONG Y. LEE

By her Representatives,

McTavish Patent Firm
429 Birchwood Courts
Birchwood, MN 55110
651-207-8270

Date March 2, 2005

By: Hugh McTavish

Hugh McTavish
Reg. No. 48,341

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United State Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 2 day of March 2005.

Hugh McTavish

Hugh McTavish